New Zealand markets close in 4 hours 13 minutes

BIIB Apr 2022 300.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.6000-0.1500 (-5.45%)
As of 03:49PM EST. Market open.
Full screen
Previous close2.7500
Open2.2600
Bid0.4000
Ask3.1000
Strike300.00
Expiry date2022-04-14
Day's range2.1000 - 2.8500
Contract rangeN/A
Volume817
Open interest515
  • Zacks

    Ionis' (IONS) Partner to Begin New Huntington's Disease Study

    Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

  • Motley Fool

    Is Biogen a Buy After the Latest Aduhelm Disaster?

    Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.

  • Motley Fool

    Where Will Biogen Be in 5 Years?

    Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022. The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store?